Creative Medical Technology Holdings Inc (CELZ)

$1.15 +0.07 (6.48%)
Market Cap 7.25M
Revenue (ttm) 10,000.00
Net Income (ttm) -6.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60,000.00%
Debt to Equity Ratio 0.00
Volume 389,663
Avg Vol 11,917,799
Day's Range N/A - N/A
Shares Out 6.59M
Stochastic %K 8%
Beta 1.95
Analysts Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Address:
211 East Osborn Road, Phoenix, United States
walker7782
walker7782 Aug. 19 at 10:33 AM
$CELZ stopped out, will keep on watch…
0 · Reply
tonneke
tonneke Aug. 18 at 12:43 PM
$CELZ Come on, now the other way 💪
0 · Reply
Martian_Paradisee
Martian_Paradisee Aug. 17 at 11:02 PM
$CELZ why?
1 · Reply
Goose_Fcker
Goose_Fcker Aug. 17 at 5:55 PM
$CELZ
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 4:11 PM
$CELZ 8350 fellow! SUCKERED.
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 4:10 PM
$CELZ Big ass HAIRCUT !
0 · Reply
URUWOLF
URUWOLF Aug. 17 at 3:53 PM
$CELZ 1.60 Warrants are useless for Hedge Funds Not 1.60 This week, 1
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 3:41 PM
$CELZ we got any new suckers, l o l
0 · Reply
tonneke
tonneke Aug. 17 at 3:16 PM
$CELZ I had imagined Monday differently 🤷‍♂️
0 · Reply
URUWOLF
URUWOLF Aug. 17 at 2:10 PM
$CELZ 1 0.70
1 · Reply
Latest News on CELZ
Creative Medical receives notice of allowance for new U.S. patent

2026-08-06T13:41:00.000Z - 13 days ago

Creative Medical receives notice of allowance for new U.S. patent

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Aug 6, 2026, 9:15 AM EDT - 13 days ago

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Creative Medical files to sell 5.58M shares of common stock for holders

2026-07-24T20:10:19.000Z - 25 days ago

Creative Medical files to sell 5.58M shares of common stock for holders

Creative Medical Technology Holdings Issues Mid-Year Update

Jul 1, 2026, 9:00 AM EDT - 7 weeks ago

Creative Medical Technology Holdings Issues Mid-Year Update

Creative Medical announces agreements for exercise of warrants for $4.5M

2026-06-30T18:10:11.000Z - 7 weeks ago

Creative Medical announces agreements for exercise of warrants for $4.5M

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Jun 30, 2026, 2:07 PM EDT - 7 weeks ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Why Did Penny Stock Creative Medical Technology Holdings (CELZ) Rocket Higher Today?

2026-06-30T14:29:25.000Z - 7 weeks ago

Why Did Penny Stock Creative Medical Technology Holdings (CELZ) Rocket Higher Today?

Creative Medical files to sell 3.05M shares of common stock

2026-06-25T20:10:16.000Z - 7 weeks ago

Creative Medical files to sell 3.05M shares of common stock

Creative Medical expands ADAPT trial under new FDA clearance

2026-06-22T13:55:45.000Z - 2 months ago

Creative Medical expands ADAPT trial under new FDA clearance

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

Jun 22, 2026, 9:15 AM EDT - 2 months ago

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

Creative Medical launches national veteran data collection for Project PHOENIX

2026-06-16T13:30:34.000Z - 2 months ago

Creative Medical launches national veteran data collection for Project PHOENIX

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Creative Medical knee data ‘highly positive,’ says Roth Capital

2026-04-28T15:53:14.000Z - 4 months ago

Creative Medical knee data ‘highly positive,’ says Roth Capital

Creative Medical reports pilot study of Ultrasome meets priamry endpoint

2026-04-28T13:57:36.000Z - 4 months ago

Creative Medical reports pilot study of Ultrasome meets priamry endpoint

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

Apr 28, 2026, 9:01 AM EDT - 4 months ago

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

Creative Medical achieves second WHO INN milestone

2026-02-10T14:06:26.000Z - 6 months ago

Creative Medical achieves second WHO INN milestone

Creative Medical announces interim data from ADAPT trial of CELZ-201

2026-01-13T14:25:23.000Z - 7 months ago

Creative Medical announces interim data from ADAPT trial of CELZ-201

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Jan 13, 2026, 9:15 AM EST - 7 months ago

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative

2026-01-06T14:25:33.000Z - 8 months ago

Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Jan 6, 2026, 9:15 AM EST - 8 months ago

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Creative Medical completes enrollment in ADAPT trial for CELZ-201

2025-12-17T14:20:20.000Z - 8 months ago

Creative Medical completes enrollment in ADAPT trial for CELZ-201

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Dec 17, 2025, 9:15 AM EST - 8 months ago

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Creative Medical announces WHO approval of olastrocel as INN for CELZ-201

2025-12-02T14:25:30.000Z - 9 months ago

Creative Medical announces WHO approval of olastrocel as INN for CELZ-201

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Dec 2, 2025, 9:15 AM EST - 9 months ago

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Creative Medical launches Biodefense Inc. Veterans Initiative

2025-10-30T13:20:14.000Z - 10 months ago

Creative Medical launches Biodefense Inc. Veterans Initiative

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Oct 30, 2025, 9:15 AM EDT - 10 months ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Creative Medical announces agreements for warrant exercise for $4.2M proceeds

2025-10-29T13:10:43.000Z - 10 months ago

Creative Medical announces agreements for warrant exercise for $4.2M proceeds

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Oct 29, 2025, 9:00 AM EDT - 10 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Creative Medical issues letter to shareholders

2025-10-27T12:30:51.000Z - 10 months ago

Creative Medical issues letter to shareholders

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 27, 2025, 8:15 AM EDT - 10 months ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Oct 7, 2025, 9:15 AM EDT - 11 months ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Creative Medical secures FDA Fast Track designation for CELZ-201-DDT

2025-08-13T13:10:11.000Z - 1 year ago

Creative Medical secures FDA Fast Track designation for CELZ-201-DDT

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 17, 2025, 9:15 AM EDT - 1 year ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Jul 11, 2025, 8:01 AM EDT - 1 year ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 20, 2025, 7:50 AM EDT - 1 year ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Mar 6, 2025, 8:10 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 14, 2025, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 11, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Feb 5, 2025, 8:25 AM EST - 1 year ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Jan 30, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 24, 2024, 9:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 7, 2024, 9:15 AM EST - 2 years ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Mar 6, 2024, 7:00 AM EST - 2 years ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Aug 24, 2023, 10:45 AM EDT - 3 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 14, 2023, 9:00 AM EDT - 3 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 12, 2023, 8:01 AM EDT - 3 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Creative Medical Technology Holdings Announces Reverse Stock Split

Jun 9, 2023, 12:30 PM EDT - 3 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 31, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 22, 2023, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

May 18, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 21, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Mar 7, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 14, 2023, 8:00 AM EST - 3 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 4 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Oct 20, 2022, 8:00 AM EDT - 4 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Sep 26, 2022, 8:00 AM EDT - 4 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

walker7782
walker7782 Aug. 19 at 10:33 AM
$CELZ stopped out, will keep on watch…
0 · Reply
tonneke
tonneke Aug. 18 at 12:43 PM
$CELZ Come on, now the other way 💪
0 · Reply
Martian_Paradisee
Martian_Paradisee Aug. 17 at 11:02 PM
$CELZ why?
1 · Reply
Goose_Fcker
Goose_Fcker Aug. 17 at 5:55 PM
$CELZ
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 4:11 PM
$CELZ 8350 fellow! SUCKERED.
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 4:10 PM
$CELZ Big ass HAIRCUT !
0 · Reply
URUWOLF
URUWOLF Aug. 17 at 3:53 PM
$CELZ 1.60 Warrants are useless for Hedge Funds Not 1.60 This week, 1
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 3:41 PM
$CELZ we got any new suckers, l o l
0 · Reply
tonneke
tonneke Aug. 17 at 3:16 PM
$CELZ I had imagined Monday differently 🤷‍♂️
0 · Reply
URUWOLF
URUWOLF Aug. 17 at 2:10 PM
$CELZ 1 0.70
1 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 17 at 2:00 PM
$CELZ so double bottom?
0 · Reply
URUWOLF
URUWOLF Aug. 17 at 1:57 PM
$CELZ Warrants 1
0 · Reply
walker7782
walker7782 Aug. 14 at 10:22 PM
$CELZ Still holding this at 1.24 waiting for warrant exercise price at $1.60…
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 7:27 PM
$CELZ
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 5:45 PM
$CELZ markets taking a dump and this is holding up, why would they wait?
0 · Reply
URUWOLF
URUWOLF Aug. 14 at 5:40 PM
$CELZ The hedge funds are holding the $1.17–$1.18 support area for now. We understand what’s happening. As soon as they allow those support levels to break, we could see 300,000 shares hit the sell side. Then you’ll see how quickly the price can drop. $0.90–$0.80 could come very easily.
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 5:00 PM
$CELZ
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 4:10 PM
$CELZ trying to be wrong some more?
0 · Reply
URUWOLF
URUWOLF Aug. 14 at 2:53 PM
$CELZ Today 1.10 ???
0 · Reply
Zephix
Zephix Aug. 13 at 8:33 PM
$CELZ night16
0 · Reply
David_M_
David_M_ Aug. 13 at 5:14 PM
$CELZ
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 13 at 4:53 PM
$CELZ looks like it going up captain told ya so....
0 · Reply